In the field of transplantation, the effects of C1-q–positive DSAs on the development of AMR and the incidence of glomerulopathy, as well as the prognosis of transplantation outcomes, have been reported administration of the humanized anti-C5 monoclonal antibody eculizumab, a C5 inhibitor, inhibits the cleavage of C5 to C5a and C5b and the formation of the membrane attack complex C5b-9, and this drug is effective against acute AMR, as indicated by its effective improvement of histopathology in lung transplantation (76–79). The gene discussed is C5; the disease is lipoprotein glomerulopathy.